Market research
2Y3.F Bionano Genomics, Inc
F EUR Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 135M
- P/E ratio
- Not available
- Analyst target
- 11.5
- Dividend yield
- 0.0%
- Beta
- 2.13
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- Not available
- Market cap
- 135M
- P/E ratio
- Not available
- Analyst target
- 11.5
- Dividend yield
- 0.0%
- Beta
- 2.13
About
About Bionano Genomics, Inc
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Research context
Bionano Genomics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 2Y3.F discussion.
5 years, 6 months ago
Bionano Genomics, Inc is currently in a long term uptrend where the price is trading 18.6% above its 200 day moving average.
From a valuation standpoint, the stock is 93.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 92.4.
Bionano Genomics, Inc's total revenue rose by 43.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 48.5% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 27.3% to $-12M since the same quarter in the previous year.
Based on the above factors, Bionano Genomics, Inc gets an overall score of 3/5.